In public debate, some issues evolve quietly, almost under the radar. Endocrine disruptors are one of them.
These chemical substances, capable of interfering with the hormonal system, are now associated with a wide range of health risks. The European Commission defines them as substances that can “alter the function of the endocrine system and consequently cause adverse health effects.”
Despite the scale of the issue, it remains relatively underrepresented in political discussions. This is precisely where certain lawmakers play a crucial role.
A Political Effort That Remains Largely Under the Radar
Unlike other major public health challenges, the response to endocrine disruptors has not been driven by large-scale political mobilization. Instead, progress often emerges through targeted initiatives led by a limited number of engaged policymakers.
In France, several lawmakers have contributed to bringing attention to the issue. Laurianne Rossi notably co-led a parliamentary mission focusing on endocrine disruptors in plastics, helping raise political awareness. Alongside her, Claire Pitollat highlighted the risks associated with everyday exposure, particularly through consumer products.
These efforts build on earlier engagement from figures such as Gérard Bapt, who played a key role in advancing the ban of bisphenol A in France.
At the European level, the issue has also been actively debated within EU institutions, where many regulatory decisions are shaped. Several Members of the European Parliament have contributed to pushing for stricter approaches to endocrine disruptors. Among them, Michèle Rivasi has been a prominent voice on environmental health, advocating for stronger application of the precautionary principle. Bas Eickhout and Sirpa Pietikäinen have also been involved in advancing more ambitious chemical policies at the EU level.
Together, these contributions illustrate how sustained — even if relatively discreet — political engagement can help bring complex scientific issues into the legislative arena.
A Regulatory Framework Still in Progress
One of the major challenges lies in the complexity of regulation, particularly at the European level where much of the relevant legislation is defined.
As emphasized by the European Commission, there is still no fully harmonized regulatory framework specifically addressing endocrine disruptors in certain sectors, including cosmetics.
Currently:
- some substances are banned if classified as carcinogenic or toxic to reproduction
- others are assessed on a case-by-case basis
- and several remain insufficiently characterized due to limited scientific data
The report also highlights that many potentially harmful substances have not yet been clearly identified, often due to gaps in available evidence.
At the same time, the European Commission — under the responsibility of figures such as Stella Kyriakides and Virginijus Sinkevičius — has been working toward a more comprehensive approach through the EU Chemicals Strategy for Sustainability.
A Public Health Issue Still Underestimated
The widespread nature of exposure makes this issue particularly complex. Endocrine disruptors can be found in:
- plastics
- cosmetics
- everyday consumer products
Their effects are often linked to cumulative exposure, making risk assessment and regulatory decisions more difficult.
This is precisely why parliamentary work plays a critical role: it helps translate scientific findings into policy discussions and contributes to accelerating regulatory action — both at national and European levels.
Recognizing These Commitments — and Their Potential
At a time when environmental and health concerns are gaining increasing attention, recognizing the role of these policymakers is essential.
Their work — often technical and not widely publicized — contributes to shaping regulatory approaches and strengthening public health protection.
More broadly, the issue of endocrine disruptors highlights a structural dynamic: meaningful progress often depends on consistent but underrecognized political engagement, often across multiple levels of governance.
Bringing greater visibility to these efforts may not only acknowledge past contributions, but also help encourage further action on an issue that remains both complex and urgent.
Reference
European Commission (2018). Review of Regulation (EC) No 1223/2009 on cosmetic products with regard to substances with endocrine-disrupting properties.